BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28573622)

  • 1. Assessment of Inhibition of Ebola Virus Progeny Production by Antiviral Compounds.
    Falzarano D
    Methods Mol Biol; 2017; 1628():203-210. PubMed ID: 28573622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput drug screening using the Ebola virus transcription- and replication-competent virus-like particle system.
    Lee N; Shum D; König A; Kim H; Heo J; Min S; Lee J; Ko Y; Choi I; Lee H; Radu C; Hoenen T; Min JY; Windisch MP
    Antiviral Res; 2018 Oct; 158():226-237. PubMed ID: 30149038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teicoplanin inhibits Ebola pseudovirus infection in cell culture.
    Wang Y; Cui R; Li G; Gao Q; Yuan S; Altmeyer R; Zou G
    Antiviral Res; 2016 Jan; 125():1-7. PubMed ID: 26585243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a coumarin-based antihistamine-like small molecule as an anti-filoviral entry inhibitor.
    Cheng H; Schafer A; Soloveva V; Gharaibeh D; Kenny T; Retterer C; Zamani R; Bavari S; Peet NP; Rong L
    Antiviral Res; 2017 Sep; 145():24-32. PubMed ID: 28645623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Ebola and Marburg Virus Entry by G Protein-Coupled Receptor Antagonists.
    Cheng H; Lear-Rooney CM; Johansen L; Varhegyi E; Chen ZW; Olinger GG; Rong L
    J Virol; 2015 Oct; 89(19):9932-8. PubMed ID: 26202243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel Small Molecule Entry Inhibitors of Ebola Virus.
    Basu A; Mills DM; Mitchell D; Ndungo E; Williams JD; Herbert AS; Dye JM; Moir DT; Chandran K; Patterson JL; Rong L; Bowlin TL
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S425-34. PubMed ID: 26206510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An RNA polymerase II-driven Ebola virus minigenome system as an advanced tool for antiviral drug screening.
    Nelson EV; Pacheco JR; Hume AJ; Cressey TN; Deflubé LR; Ruedas JB; Connor JH; Ebihara H; Mühlberger E
    Antiviral Res; 2017 Oct; 146():21-27. PubMed ID: 28807685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing Antiviral Countermeasures Using Mouse Models of Ebolavirus Infection.
    Kroeker A; Griffin BD; Qiu X; Kobinger G
    Methods Mol Biol; 2017; 1628():273-282. PubMed ID: 28573628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Ellagic Acid from Plant Rhodiola rosea L. as an Anti-Ebola Virus Entry Inhibitor.
    Cui Q; Du R; Anantpadma M; Schafer A; Hou L; Tian J; Davey RA; Cheng H; Rong L
    Viruses; 2018 Mar; 10(4):. PubMed ID: 29584652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an antioxidant small-molecule with broad-spectrum antiviral activity.
    Panchal RG; Reid SP; Tran JP; Bergeron AA; Wells J; Kota KP; Aman J; Bavari S
    Antiviral Res; 2012 Jan; 93(1):23-9. PubMed ID: 22027648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A high throughput screen identifies benzoquinoline compounds as inhibitors of Ebola virus replication.
    Luthra P; Liang J; Pietzsch CA; Khadka S; Edwards MR; Wei S; De S; Posner B; Bukreyev A; Ready JM; Basler CF
    Antiviral Res; 2018 Feb; 150():193-201. PubMed ID: 29294299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Diaryl-Quinoline Compounds as Entry Inhibitors of Ebola Virus.
    Cui Q; Cheng H; Xiong R; Zhang G; Du R; Anantpadma M; Davey RA; Rong L
    Viruses; 2018 Nov; 10(12):. PubMed ID: 30513600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing the antiviral potency of ER α-glucosidase inhibitor IHVR-19029 against hemorrhagic fever viruses in vitro and in vivo.
    Ma J; Zhang X; Soloveva V; Warren T; Guo F; Wu S; Lu H; Guo J; Su Q; Shen H; Solon E; Comunale MA; Mehta A; Guo JT; Bavari S; Du Y; Block TM; Chang J
    Antiviral Res; 2018 Feb; 150():112-122. PubMed ID: 29253498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Throughput Screening Using a Whole-Cell Virus Replication Reporter Gene Assay to Identify Inhibitory Compounds against Rift Valley Fever Virus Infection.
    Islam MK; Baudin M; Eriksson J; Öberg C; Habjan M; Weber F; Överby AK; Ahlm C; Evander M
    J Biomol Screen; 2016 Apr; 21(4):354-62. PubMed ID: 26762502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lassa and Ebola virus inhibitors identified using minigenome and recombinant virus reporter systems.
    Welch SR; Guerrero LW; Chakrabarti AK; McMullan LK; Flint M; Bluemling GR; Painter GR; Nichol ST; Spiropoulou CF; Albariño CG
    Antiviral Res; 2016 Dec; 136():9-18. PubMed ID: 27771389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule inhibitors of ebola virus infection.
    Picazo E; Giordanetto F
    Drug Discov Today; 2015 Feb; 20(2):277-86. PubMed ID: 25532798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling the Ebolavirus Life Cycle with Transcription and Replication-Competent Viruslike Particle Assays.
    Biedenkopf N; Hoenen T
    Methods Mol Biol; 2017; 1628():119-131. PubMed ID: 28573615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repurposing Quinacrine against Ebola Virus Infection
    Lane TR; Comer JE; Freiberg AN; Madrid PB; Ekins S
    Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral effect of ranpirnase against Ebola virus.
    Hodge T; Draper K; Brasel T; Freiberg A; Squiquera L; Sidransky D; Sulley J; Taxman DJ
    Antiviral Res; 2016 Aug; 132():210-8. PubMed ID: 27350309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks.
    Haque A; Hober D; Blondiaux J
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5892-902. PubMed ID: 26248374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.